• Molecular formula: C21H30N3NaO8S
  • CAS# 1416992-39-6
  • Molecular mass: 507.5 g/mol
  • Sodium (2S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanamido)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate
  • Synonymum – H1NMJ5XDG5
  • Patent# US9474759B2
    Owner: Kansas State University
  • ChemSrc, PubChem
  • Wiki

GC376 is a broad-spectrum antiviral medication under development by the biopharmaceutical company Anivive Lifesciences for therapeutic uses in humans and animals.[1] Anivive licensed the exclusive worldwide patent rights to GC376 from Kansas State University. As of 2020, GC376 is being investigated as treatment for COVID-19. GC376 shows activity against many human and animal viruses including coronavirus and norovirus; the most extensive research has been multiple in vivo studies in cats treating a coronavirus which causes deadly feline infectious peritonitis. Other research supports use in porcine epidemic diarrhea virus.

Mechanism of action

GC376 je inhibítor 3C (3C-Like) proteázy. Proteáza je enzým, ktorý je kľúčovo dôležitým katalyzátorom pre proteolýzu – štiepenie peptidových väzieb vírusových polyproteínov, ako aj pre spojenie častí vírusu do funkčného celku a „dozretie“ vírusu. GC376 blokuje činnosť proteázy, čím prerušuje životný cyklus vírusu, ktorý sa tak už nemôže ďalej replikovať.

Preparation of injection solution with GC376

GC376 is dissolved for injection use in a solution consisting of 10% ethanol and 90% PEG-400.

Field trial study and commercialization

In September 2017, a field trial study entitled Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis, whose main authors are Dr. Niels Pedersen and Yunjeong Kim. This study clearly demonstrated the efficacy of GC376 in the treatment of FIP. The company which is trying to approve the medicine and place it on the market is Anivive. The launch could take place sometime around 2023.

GC376 is currently a bit forgotten, as GS441524 is mainly used to treat FIP. However, GC376 still appears to be justified, for example, in a situation where resistance to GS441524 develops. In addition, it is possible that future drugs for FIP will contain both active ingredients GS441524 and GC376, as they complement each other, which may lead to their synergistic therapeutic effect.